No Matches Found
No Matches Found
No Matches Found
Hindustan Bio Sciences Ltd
Hindustan Bio Sciences Ltd Upgraded to Sell Amid Mixed Technical and Fundamental Signals
Hindustan Bio Sciences Ltd, a micro-cap player in the Software Products sector, has seen its investment rating upgraded from Strong Sell to Sell as of 7 April 2026. This change is primarily driven by a shift in technical indicators signalling a mildly bullish trend, despite persistent weaknesses in the company’s financial fundamentals and valuation metrics.
Golden Cross Forms in Hindustan Bio Sciences Ltd — On a Day the Stock Fell 4.9%. What the Mixed Signals Mean
The 50-day moving average has crossed above the 200-day moving average for Hindustan Bio Sciences Ltd, signalling a golden cross on 7 Apr 2026. Yet, the stock declined 4.94% on the same day, while monthly momentum indicators remain bearish. This divergence between the moving averages and price action calls for a detailed examination of the signal's reliability.
Hindustan Bio Sciences Ltd Gains 21.01%: Valuation and Quality Concerns Shape the Week
Hindustan Bio Sciences Ltd delivered a strong weekly performance, surging 21.01% from Rs.6.76 to Rs.8.18 between 2 and 6 February 2026, significantly outperforming the Sensex’s modest 1.51% gain over the same period. This rally unfolded amid a backdrop of fundamental downgrades, valuation concerns, and mixed technical signals, reflecting a complex interplay of market optimism and caution.
Hindustan Bio Sciences Ltd Downgraded to Strong Sell Amid Weak Fundamentals and Expensive Valuation
Hindustan Bio Sciences Ltd has been assigned a Strong Sell rating with a Mojo Score of 21.0, reflecting significant concerns across quality, valuation, financial trends, and technical indicators. The downgrade from a previously ungraded status follows a comprehensive reassessment revealing deteriorating fundamentals, expensive market valuation, and mixed technical signals despite recent price gains.
Hindustan Bio Sciences Ltd Valuation Shifts Signal Elevated Price Risk
Hindustan Bio Sciences Ltd, a player in the Software Products sector, has seen a marked shift in its valuation parameters, moving from a risky to a very expensive rating. Despite a strong short-term price rally, the company’s elevated price-to-earnings and price-to-book ratios raise questions about its price attractiveness relative to historical averages and peer benchmarks.
Hindustan Bio Sciences Ltd Quality Grade Downgrade Highlights Fundamental Challenges
Hindustan Bio Sciences Ltd has seen its quality grade downgraded from "Does Not Qualify" to "Below Average" as of 1 February 2026, reflecting deteriorations in key business fundamentals. Despite a recent surge in share price, the company’s financial metrics reveal challenges in profitability, capital efficiency, and growth consistency, raising concerns for investors in the Software Products sector.
Hindustan Bio Sciences Q3 FY26: Profitability Returns But Volatility Remains High
Hindustan Bio Sciences Ltd., a micro-cap pharmaceutical company with a market capitalisation of just ₹7.00 crores, posted a net profit of ₹0.08 crores in Q3 FY26 (October-December 2025), marking a sharp recovery from the ₹0.06 crore loss reported in the previous quarter. The stock surged 4.88% to ₹7.09 on February 1, 2026, though it remains 31.30% below its 52-week high of ₹10.32 amid persistent concerns about operational stability and financial sustainability.
When is the next results date for Hindustan Bio Sciences Ltd?
The next results date for Hindustan Bio Sciences Ltd is January 31, 2026.
Why is Hind.Bio Science falling/rising?
On 28-Nov, Hindustan Bio Sciences Ltd witnessed a notable decline in its share price, closing at ₹6.10, down by ₹0.20 or 3.17% as of 08:35 PM. This drop marks a fresh 52-week low for the stock, reflecting ongoing challenges despite increased investor activity.
Why is Hind.Bio Science falling/rising?
As of 18-Nov, Hindustan Bio Sciences Ltd's stock price is Rs 6.59, down -4.91%, and has fallen -9.6% over the last two days. The stock is trading below all key moving averages and is close to its 52-week low, with significantly decreased investor participation.
Is Hind.Bio Science overvalued or undervalued?
As of November 3, 2025, Hind.Bio Science is considered overvalued with a PE ratio of 54.70, significantly higher than its peers, and has underperformed the Sensex year-to-date, indicating a risky investment.
How has been the historical performance of Hind.Bio Science?
Hind.Bio Science has experienced fluctuating financial performance, with net sales declining from 3.56 Cr in Mar'19 to 0.81 Cr in Mar'25, though profitability metrics show signs of recovery, particularly with an operating profit margin improving to 12.35% in Mar'25. Total liabilities and assets have also decreased during this period, while cash flow from operations has remained stagnant.
Why is Hind.Bio Science falling/rising?
As of 30-Oct, Hindustan Bio Sciences Ltd's stock price is at 7.14, up 5.0% recently, but it has declined 15.00% over the past month and 30.07% year-to-date. Despite a short-term gain, the stock's delivery volume has dropped significantly, indicating reduced investor interest.
Why is Hind.Bio Science falling/rising?
As of 24-Oct, Hindustan Bio Sciences Ltd's stock price is Rs. 6.57, down 9.88% and at a new 52-week low, having declined 26.92% over the past three days. The stock has underperformed its sector and major benchmarks, despite a notable increase in delivery volume, indicating limited investor interest amidst a broader market recovery.
Why is Hind.Bio Science falling/rising?
As of 23-Oct, Hindustan Bio Sciences Ltd's stock price is at 7.29, down 10.0%, and has underperformed significantly with an 18.91% total return drop over two days. It is trading below all moving averages, indicating a bearish trend, and has seen a 65.19% decrease in delivery volume, reflecting reduced investor participation.
Why is Hind.Bio Science falling/rising?
As of 20-Oct, Hindustan Bio Sciences Ltd's stock price has risen to 8.99, reflecting an increase of 8.97%. The stock has shown strong short-term performance, outperforming the Sensex, but has underperformed year-to-date.
When is the next results date for Hind.Bio Science?
Hind.Bio Science will announce its results on 31 October 2025.
Why is Hind.Bio Science falling/rising?
As of 15-Oct, Hindustan Bio Sciences Ltd's stock price is at 8.49, having increased by 8.85% today after five days of decline, with significant investor participation indicated by an 83.17% rise in delivery volume. Despite a year-to-date decline of 16.85%, the stock has shown strong long-term performance with an 87.83% return over three years.
Why is Hind.Bio Science falling/rising?
As of 13-Oct, Hindustan Bio Sciences Ltd's stock price is declining at 7.97, down 3.39%, and has underperformed its sector. The stock is trading below all major moving averages, with a significant drop in investor participation and a year-to-date decline of 21.94%.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}

